MedTrace Logo

Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis

NCT04834401 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2022-08-18

No results posted yet for this study

Summary

This observational study is intended to evaluate the effect of disease modifying therapies on antibody responses to the mRNA-1273 vaccine (Moderna) for COVID-19. We hypothesize that the use of certain disease modifying therapies, particularly ocrelizumab, will mute and/or shorten the duration of humoral response to mRNA vaccines.

Conditions

Sponsors & Collaborators

  • St. Barnabas Medical Center

    lead OTHER

Principal Investigators

  • Matthew A Tremblay, MD, PhD · RWJBarnabas Health

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2022-05-17
Completion
2022-05-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04834401 on ClinicalTrials.gov